Greg has been a life-long pioneer in childhood cancer and has literally never taken his foot off the accelerator. With his broad background in haematology, cancer in infants and early phase trials, he was a natural choice to lead the formation of a single clinical research organisation for children’s cancers across the entire USA and Canada, the COG, over 20 years ago.

He was successful in negotiating with governmental funding sources to ensure that the COG has had the capabilities to run practice-setting clinical trials across all childhood cancer types, with associated translational and basic science research to improve understanding of risk factors and aetiologies. This approach has been a global exemplar, with outputs benefiting children beyond the COG, and with enduring global impact.

He has used his position in an HIC to show how the need for therapeutic innovation for children with cancer worldwide can be addressed. He was instrumental in working with the US FDA to encourage regulatory incentives for paediatric drug development. More recently, he spearheaded the ACCELERATE collaboration involving the European Medicines Agency, the FDA, industry, academia and parents/survivors to create Paediatric Strategy Forums for specific medicinal product development. In his new role as director of the CCDI, he will ensure cancer data gives maximum learning for all.

Greg has worked tirelessly for SIOP as Treasurer (2014-2020) and continues as an advisor to the SIOP PARC Program. He has supported the SIOP Global Health Network’s work and the development of cooperative groups in LATAM.